Clinical trials: Nash
Non-alcoholic Fatty Liver Disease NAFLD
Hepatic Mitochondrial Metabolism in Fatty Liver Disease in Humans
The goal of this clinical trial is to investigate in healthy volunteers the mechanisms by which ethanol and lipids, the two key risk factors of steatotic liver disease (SLD), affect liver mitochondrial metabolism.
- Trial name
- ALPHA (NCT06559878)
- Testing
- 13C-α-Ketoisocaproic Acid Breath Test, Ethanol, Lipid Emulsion
- Where
- Finland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Non - Alcoholic Steatohepatitis
A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects
The safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics study of HEC169584 capsules in healthy subjects .
- Trial name
- NCT07099118
- Testing
- HEC169584 capsule
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
NAFLD, Precision Medicine
The Liver BIoBank Lombardia of Fatty Liver
NAFLD is most frequently linked to excess adiposity, insulin resistance and cardiometabolic risk factors, it has become the leading cause of liver disease worldwide, and is associated with increased mortality due to multiple…
- Conditions
- NAFLD, Precision Medicine, Cardiovascular Diseases
- Trial name
- NCT06566105
- Testing
- precision medicine approach
- Where
- Italy
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Liver Cirrhoses
Risk Factors of Liver Fibrosis Among First Degree Relatives of Patients With NASH Related Cirrhosis (NRC)
The study aim to identify the risk factors of liver fibrosis among first degree relatives. This study consists of 2 parts (Cross Sectional and Case Control Study).
- Trial name
- NCT04057287
- Testing
- No intervention
- Where
- India
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- Institute of Liver and Biliary Sciences, India
Overweight, Fatty Liver Disease
The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults
To assess whether orange peel fermentation has the effect of reducing body fat in adults
- Trial name
- NCT04496895
- Testing
- orange peel fermentation
- Where
- Taiwan
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Non-Alcoholic Fatty Liver Disease, Glucagon Resistance
The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover
Many patients with type 2 diabetes exhibit elevated plasma concentrations of the glucose-mobilising pancreatic hormone glucagon; i.e. hyperglucagonaemia.
- Trial name
- NCT04859322
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Malte Palm Suppli, MD
NASH - Nonalcoholic Steatohepatitis
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.
To evaluate the safety, tolerability and Pharmacokinetic profile of SNP-630 when oral administered to healthy subjects.
- Trial name
- NCT04808154
- Testing
- SNP-630
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sinew Pharma Inc.
Obesity Prevention, Pediatric Obesity
Relationship Between Eating Patterns, Body Composition and the Detection of Fatty Liver in Children and Adolescents With Trisomy 21: LiverTy Project
Childhood obesity is a growing public health issue affecting millions of children worldwide, increasing the risk of metabolic and cardiovascular diseases in adulthood.
- Conditions
- Obesity Prevention, Pediatric Obesity, Trisomy 21, Down Syndrome (Trisomy 21)
- Trial name
- LiverTy (NCT06888570)
- Testing
- To evaluate fat liver content in the cases/controls population.
- Where
- Spain
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- IMDEA Food
Obesity, Childhood, NAFLD
Can Fecal Calprotectin Be Used as a Biomarker of Non-alcoholic Fatty Liver Disease In Obese Adolescents?
The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that ongoing inflammation in obesity and alterations in the enterohepatic axis contribute to this process.
- Trial name
- NCT06229184
- Testing
- Fecal Calprotectin Test
- Where
- Turkey (Türkiye)
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
Non-Alcoholic Fatty Liver Disease
The Effect of an RBAC Supplement (BRM4) on NAFLD
The purpose of this study is to investigate the effects of Rice Bran Arabinoxylan Compound (RBAC) on outcome variables in persons with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT02568787
- Testing
- rice bran arabinoxylan compound (RBAC)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Miami
Colorectal Neoplasms, Nonalcoholic Fatty Liver Disease
Study of the Association of Nonalcoholic Fatty Liver Disease With Colorectal Malignant Neoplasm
The aim of this sudy is to investigate the prevalence of colorectal cancer (CRC) in patients with nonalcoholic fatty liver disease (NAFLD) and evaluate whether NAFLD is a risk factor for CRC.
- Trial name
- NWC (NCT01657773)
- Testing
- Ultrasound examination and Colonoscopy examination
- Where
- China
- Volunteers
- 2,315 people, healthy volunteers welcome
- Sponsor
- Wenzhou Medical University
Non-alcoholic Fatty Liver Disease (NAFLD)
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease
The goal of this observational, cross-sectional, case-control clinical study is to investigate the metabolic adaptations underlying the progression of nonalcoholic fatty liver disease (NAFLD), and to test the hypothesis that…
- Trial name
- ECHO (NCT06942312)
- Testing
- Ketoisocaproic acid breath test, Ammonium Chloride, Bicarbonate de sodium
- Where
- Finland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Nonalcoholic Steatohepatitis
Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers
Fasting Period: At least 10 hours prior to dosing until 4 hours post-dose of each study period. Period: 24 hours post dose in each period. Each subject will complete two study periods.
- Trial name
- NCT05983328
- Testing
- HUYPS-1 one tablet, HUYPS-1 nine tablets
- Where
- Taiwan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sinew Pharma Inc.
Hepatic Fat Accumulation, Nonalcoholic Fatty Liver Disease
Dietary Protein and Hepatic Fat Accumulation
The objective of this study is to investigate the potential beneficial effect of increasing protein in the diet in order to decrease hepatic lipid accumulation on a high-fat diet.
- Trial name
- LiF-Pro (NCT01354626)
- Testing
- dietary protein, low-protein
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Wageningen University
Nonalcoholic Fatty Liver Disease
Observational Study About Patients Diagnosed With NAFLD
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome.
- Trial name
- NCT05625750
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Moderate Liver Impairment, Severe Liver Impairment
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment.
- Trial name
- NCT04634149
- Testing
- BMS-986036
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Non-alcoholic Fatty Liver Disease
A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - Food Effect (FE) phase, and Part C - multiple ascending dose (MAD) phase.
- Trial name
- NCT05063968
- Testing
- XZP-6019 tablet
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss
Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging or by biopsy and absence of causes for secondary hepatic fat accumulation such as…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss, Non-alcoholic Steatohepatitis (NASH)
- Trial name
- CGH-LiNASH (NCT02654665)
- Testing
- Lifestyle modification, Liraglutide
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
Non-Alcoholic Fatty Liver Disease, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH
A study for evaluating the improvement effect on Metabolic dysfunction-associated steatotic liver disease (MASLD) of probiotics Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with dysbiosis of the…
- Trial name
- NCT04555434
- Testing
- Probiotics
- Where
- South Korea
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Type2 Diabetes
Identification and Validation of Noninvasive Biomarkers of the Diagnosis and Severity of NASH in Type 2 Diabetics
Metabolic diseases of the liver are silent affections whose morbidity is important. About 70% of patients with type 2 diabetes (T2D) are concerned.
- Trial name
- Quid-Nash (NCT03634098)
- Testing
- new quantitative imaging techniques with contast products, blood sample, second generation tests
- Where
- France
- Volunteers
- 970 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris